Please use this identifier to cite or link to this item: http://hdl.handle.net/10637/15397
Full metadata record
DC FieldValueLanguage
dc.contributor.otherGrupo: Spanish Back Pain Research Network (REIDE)-
dc.creatorGarcía Romero, Noemí-
dc.creatorPalacín Aliana, Irina-
dc.creatorMadurga, Rodrigo-
dc.creatorCarrión-Navarro, Josefa-
dc.creatorEsteban Rubio, Susana-
dc.creatorJiménez, Beatriz-
dc.creatorCollazo, A.-
dc.creatorPérez-Rodríguez, Felipe-
dc.creatorOrtiz de Mendivil Arrate, Ana-
dc.creatorFernández-Carballal, C.-
dc.creatorGarcía-Duque, S.-
dc.creatorDiamantopoulos-Fernández, J.-
dc.creatorBelda Iniesta, Cristóbal-
dc.creatorPrat-Acín, R.-
dc.creatorSánchez-Gómez, P.-
dc.creatorCalvo Aller, Emiliano-
dc.creatorAyuso Sacido, Ángel-
dc.date.accessioned2024-02-08T14:19:49Z-
dc.date.available2024-02-08T14:19:49Z-
dc.date.issued2020-06-22-
dc.identifier.citationGarcía-Romero, N., Palacín-Aliana, I., Madurga, R. et al. Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. BMC Med 18, 142 (2020). https://doi.org/10.1186/s12916-020-01610-0es_ES
dc.identifier.issn1741-7015-
dc.identifier.urihttp://hdl.handle.net/10637/15397-
dc.description.abstractBackground: Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. Methods: We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment. Results: We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance. Conclusions: Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment.en_EN
dc.formatapplication/pdf-
dc.language.isoen-
dc.publisherBMC-
dc.relation.ispartofBMC Medicine-
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.es-
dc.rightsOpenAccess-
dc.subjectVEGFAen_EN
dc.subjectAngiogenesisen_EN
dc.subjectBevacizumaben_EN
dc.subjectGlioblastomaen_EN
dc.subjectNeovasculogenesisen_EN
dc.titleBevacizumab dose adjustment to improve clinical outcomes of glioblastomaen_EN
dc.typeArtículoes_ES
dc.identifier.doi10.1186/s12916-020-01610-0-
dc.relation.projectIDSupported by grants from the “Fondo de Investigaciones Sanitarias” (FIS) (PI17-01489), the Miguel Servet Program (CP11/00147) del Instituto de Salud Carlos III (AAS), and the Ministerio de Economía y Competitividad–FEDERER (RTC-2016-4990-1). IPA was supported by “Ayudas para la contratación de ayudantes de investigación cofinanciadas por el Fondo Social Europeo a través del Programa Operativo de Empleo Juvenil y la Iniciativa de Empleo Juvenil (YEI),” and SER was supported by FPI-CEU predoctoral fellowship.-
dc.centroUniversidad San Pablo-CEU-
Appears in Collections:Medicina




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.